T98

Quick links

Choose a section

Quick links to important sections

Advertisements

T98

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of T98

Property Description
Active Ingredient Paracetamol (Acetaminophen)
Form Oral Solid (Tablet), Oral Liquid (Suspension), Rectal (Suppository)
Pharmacological Class Non-opioid Analgesic, Antipyretic
Common Use Symptomatic relief of pain and fever
Origin Synthetic substance (Aniline derivative)

T98 is a trade name for a medicinal preparation whose sole active component is Paracetamol, which is chemically synonymous with Acetaminophen. It is a widely used synthetic substance clinically recognized as both a Non-opioid Analgesic (pain reliever) and an Antipyretic (fever reducer). As a foundational medicine, T98 is typically a single-agent product that achieves its general therapeutic purpose through its action within the central nervous system. Unlike other common relievers, T98 is an Aniline derivative recognized for its efficacy and often positioned for specific patient groups, such as children, through flavored Oral liquid forms.


T98 Composition and Available Forms

The efficacy of T98 is derived exclusively from the active ingredient, Paracetamol. This component is combined with various inactive excipients to formulate the physical preparation, or dosage form, for administration. T98 is made available in several pharmaceutical preparations to suit different patient needs, including Oral solid forms like tablets and caplets, as well as Oral liquid forms such as suspensions and solutions, primarily intended for Oral administration. For situations where oral intake is not feasible, the medicine can also be formulated for the Rectal route, specifically as a suppository.


The General Purpose of T98

The general purpose of T98 is the symptomatic relief of pain and fever (pyrexia). It achieves this by acting centrally to elevate the body's pain threshold and directly influencing the hypothalamic heat-regulating center in the brain. As a treatment for mild to moderate pain and fever, the medicine targets these central processes to help manage general discomfort and elevated temperatures by dampening the body’s awareness of pain signals and facilitating the reduction of fever.

Regulatory References

  1. EMA Medicine finder
Advertisements

What side effects are possible with T98?

Possible Side Effects and Safety Information

The official safety profile for T98 (Paracetamol/Acetaminophen) is defined by regulatory authorities based on documented adverse reactions and specific constraints. The most critical safety feature across all labeling is the risk of severe liver damage (Hepatotoxicity), which is associated primarily with exceeding the maximum recommended daily dose or consuming other products containing the same active ingredient.

Adverse Reaction Classifications

Side effects are categorized by frequency, though most documented events are classified as Rare or Very Rare.

Category Examples (as per regulatory labels)
Serious Reactions Severe Liver Failure, Anaphylactic Shock, Serious Skin Reactions (e.g., SJS, TEN).
System-Organ Classes Effects on the Hepato-biliary Disorders system, Blood and Lymphatic System Disorders (e.g., blood dyscrasias), Renal and Urinary Disorders, and Immune System Disorders.

Safety Constraints and Special Populations

Use is contraindicated in individuals with known hypersensitivity to the drug or those with severe hepatic impairment or severe active liver disease. Safety notes specify that caution is required for patients with severe renal impairment and those with a history of chronic alcohol consumption, as these factors significantly increase the risk of severe liver damage. Regulatory documents also link long-term or frequent use to potential renal adverse effects and the development of analgesic-induced headache.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the T98 (Paracetamol/Acetaminophen) overdose profile primarily by its potential for severe, delayed hepatotoxicity. While early symptoms may be non-specific, including nausea, vomiting, and abdominal pain, a dangerous dose can initially cause no symptoms, which does not indicate the severity of potential internal damage.

Official Regulatory Statements

Classification Detail (As Stated in Official Documents)
Documented Outcomes Severe liver damage, acute liver failure, encephalopathy, and death are documented risks [FDA; SmPC].
Antidote Status N-acetylcysteine (NAC) is the specific antidote for T98 poisoning. Its effectiveness is time-dependent and requires prompt administration [FDA].
High-Risk Groups Risk of acute liver failure is higher in individuals with underlying liver disease or chronic alcohol consumption [SmPC].
Mandatory Action Immediate medical advice must be sought in the event of an overdose, even if the patient feels well [SmPC].

This required emergency action is necessary because the antidote's effectiveness is time-critical, and rapid professional assessment, including blood level testing, is mandated to mitigate the life-threatening systemic outcomes listed by regulatory authorities.

Advertisements

Therapeutic Uses of T98

What T98 Treats: Main Uses and Benefits

T98 is applied across domains where additional symptomatic support is needed, used in situations involving certain distressing symptoms. The medication’s actions are relevant for easing symptomatic discomfort and elevated temperature.

T98 plays a role in managing symptoms related to physical discomfort and systemic imbalance.

Symptomatic Relief for Acute Discomfort

T98 is commonly used to help with symptom clusters that may become intense or disruptive, such as tension headaches, mild joint aches, dental discomfort, and pain associated with the menstrual cycle (dysmenorrhea). It is applied in clinical settings that involve acute or unstable symptom patterns, which require supportive symptomatic assistance. The medicine is generally used across conditions presenting with acute episodes, including those associated with colds and influenza. This symptomatic relief supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load.

“T98 is relevant when supportive symptom management is appropriate, applied in scenarios where additional management of discomfort is required.”

Quick Fact: Relief for Pain & Fever

T98 is commonly used across conditions presenting with acute episodes, including for children (relevant for easing fever and pain) and for adults, where short-term symptomatic assistance is appropriate. It is relevant in contexts involving heightened systemic burden, used in situations where short-term symptomatic assistance is needed for mild to moderate discomfort.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use T98 (Official Regulatory Information)

Official regulatory documents define specific populations who are eligible for T98 (Paracetamol/Acetaminophen) and those who are either strictly prohibited from use or require restrictions.

Eligibility Scope Status as Defined in Labeling
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance or any ingredient in the formulation. Patients with severe hepatic impairment or severe active liver disease [1.4, 2.1].
Populations for whom use is allowed Adults and Adolescents (generally permitted). Breastfeeding women (considered compatible with use) [1.1, 3.1].
Age-Related Eligibility Use is not recommended in the youngest infants (e.g., under 2–3 months of age) except for specific indications like post-vaccination fever. Eligibility in children is dependent on strict age and weight thresholds for the specific formulation [4.5, 4.4].

Condition-Specific Eligibility Rules

Condition/Status Regulatory Rule and Restriction
Severe Renal Impairment Use is restricted, often requiring extended minimum dosing intervals [1.4, 2.2].
Hepatic Impairment (Non-Severe) Use requires caution in patients with chronic alcoholism, chronic malnutrition, or mild to moderate hepatic impairment, due to heightened risk [1.4, 2.1].
Pregnancy Use is permitted if clinically needed, but with the formal restriction to use the lowest effective dose for the shortest possible duration [3.2, 3.5].

Connection to the Overall Eligibility Profile

The eligibility profile for T98 is structured by absolute contraindications related to allergic history and the status of the patient's liver function, given the medicine's metabolism. For other populations, such as those with kidney impairment or chronic alcohol use, use is not prohibited but is formally restricted by regulatory warnings that require caution or adjustment, and specific age thresholds determine eligibility in pediatric patients [1.2, 1.4].

Advertisements

What should I know about interactions with other medicines?

T98 Interactions with other medicines and products

Carbamazepine is known to interact with numerous other medicines and products due to its effects on liver enzymes, primarily as an enzyme inducer. This action generally results in the accelerated breakdown and reduced plasma levels of many co-administered drugs, potentially leading to their decreased effectiveness. This list is not exhaustive, and the use of other products should always be reviewed by a healthcare professional.

Category or Product Interaction Outcome
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use is not recommended; a minimum 14-day washout period is required between stopping an MAOI and starting Carbamazepine.
Hormonal Contraceptives Effectiveness is decreased; use of alternative, non-hormonal birth control methods is required.
Other Anti-seizure Medicines Levels of both Carbamazepine and the concomitant medicine (e.g., phenytoin, valproic acid) may be increased or decreased, requiring careful monitoring and dose adjustment.
Anticoagulants Effectiveness of oral anticoagulants (e.g., warfarin, apixaban) is decreased, increasing the risk of blood clots.
Grapefruit/Grapefruit Juice Inhibits Carbamazepine's metabolism, leading to increased plasma levels and a greater risk of adverse effects; complete avoidance is recommended.

Carbamazepine also has a structural relationship to tricyclic antidepressants, and its use is generally avoided in individuals with a known hypersensitivity to that class of medicine. Caution is required with other interacting agents, including certain antibiotics, antifungals, and antidepressants, as their blood concentrations may be significantly lowered by Carbamazepine's enzyme-inducing effect.

Advertisements

Mechanism of Action

Mechanism 1: Target Binding and Competitive Antagonism

T98's primary mechanism of action initiates at the cellular surface where the molecule acts as a high-affinity ligand for the A1alpha receptor. T98 is categorized as a competitive antagonist, meaning it directly occupies the receptor site, preventing the binding of endogenous molecules. This interaction is highly selective and saturable, ensuring that the initial biochemical signal is precisely modulated.


Mechanism 2: Intracellular Signal Cascade (c-Fos and NF-κB)

The binding of T98 to the A1alpha receptor transmits an intracellular signal that culminates in the reduced phosphorylation and dimerization of the c-Fos protein. The functional consequence of this reduction is the diminished nuclear translocation and subsequent activation of the NF-κB pathway. This molecular event directly impacts gene transcription, specifically altering the expression profiles of genes that are regulated by NF-κB and its associated transcription factors.


Mechanism 3: Modulation of Systemic Homeostasis

By modulating the NF-κB signaling axis, T98 affects cellular processes that govern systemic homeostatic responses. The net mechanistic effect is a measured modification of cytokine and chemokine production at the cellular level, particularly in immune-responsive tissues, influencing the overall cellular environment and its capacity for sustained activation.

Advertisements

Dosage and Administration Information

How to Use T98: Official Administration Guidelines

T98 (Paracetamol/Acetaminophen) is utilized in clinical practice through three official administration routes: Oral (tablets, solutions), Rectal (suppositories), and Intravenous (IV) for supervised settings. The regulatory framework defines precise dosing and timing requirements for proper use.


Administration Scope

The official dosing schedule for adults (aged 12 years and older) specifies a typical single dose between 500 mg and 1000 mg. Critically, the maximum dose must not exceed 1000 mg per administration, and the total intake from all sources must be limited to 4000 mg (4 g) within a 24-hour period.

Doses must be separated by a minimum interval of four hours, with a typical frequency being every four to six hours as needed. T98 may be taken with or without food.

Procedural and Time Constraints

The administration of T98 liquid forms requires a specific protocol: the suspension must be shaken well, and the dose must be measured using a calibrated device. For patients with severe hepatic or renal impairment, or for pediatric patients under 12 years, dose adjustments based on weight or condition are mandated by regulatory standards. Intravenous administration is reserved for supervised settings and must be delivered via infusion over a 15-minute duration. Furthermore, official instructions advise that the medicine should not be used for more than 10 days for pain or 3 days for fever without medical guidance. To avoid exceeding the strict daily maximum, it is a primary procedural constraint to avoid taking T98 concurrently with any other product containing acetaminophen.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for T98


Evidence for Symptomatic Relief of Acute Pain

T98 was studied in research examining the acute pain experience in numerous short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, often comparing T98 against a placebo (an inactive substance) in controlled settings. The primary outcomes measured included patient-reported Pain Intensity Scores and the Time to first measured change in pain score.

Systematic reviews and meta-analyses research described patterns observed in the studies related to changes measured during the study period. The evidence base for this acute, short-term measurement contributes to the broader evidence landscape that regulatory bodies rely on. The core evidence base for pain is limited to trials assessing short-term or episodic symptom patterns. Data for certain groups with complex health issues remain insufficient, and long-term effects are not fully established.


Evidence for Symptomatic Management of Fever (Pyrexia)

T98 was studied in research examining the symptomatic management of fever in numerous clinical trials. Research primarily focused on outcomes related to systemic or functional imbalance, specifically measuring changes in body temperature and the duration of the measured change. A large amount of this research was conducted during periods of increased symptom activity and concentrated on Febrile children.

The accumulated evidence describes patterns in how changes in body temperature were observed in the studied populations. This consistent data on outcomes linked to inflammatory or irritative states over short-term observation periods supports its inclusion in the regulatory assessment of fever.


Research Gaps and Areas of Uncertainty

The research landscape contains known limitations used in research exploring how symptoms change over time. One primary limitation is the limited information for long-term outcomes and the durability of the measured effect, as most evidence is limited to short-term observation windows. Comparative evidence is lacking in some areas. Research still explores how the evidence applies to all complex patient groups, ensuring that subgroup findings are uncertain for populations outside those commonly included in the initial registration trials.

Key Studies & References

  1. Paracetamol is ineffective for acute low back pain even for patients who comply with treatment: complier average causal effect analysis of a randomized controlled trial
Advertisements

Frequently Asked Questions (FAQ)

Common questions about T98 (FAQ)

Q: What is the expected duration of T98's effect after taking a dose?

Official administration guidelines state that T98 doses should be separated by a minimum interval of four to six hours.

This typical dosing frequency provides a general indication of how long the medicine's effect is expected to last for symptomatic relief of pain or fever.


Q: Is it common to experience headache or dizziness while taking T98?

Official product information for single-agent T98 does not typically list headache or dizziness as frequent adverse reactions.

While these effects are not commonly reported with the single-agent product, they may be present in formulations where T98 is combined with other types of medicine.


Q: Is T98 safe for use in older adults (seniors)?

Regulatory sources advise specific caution for older adults due to the risk of potential liver toxicity.

Some health organizations advise limiting the total daily dose for older adults to 3 grams or less, which is a reduction from the general adult maximum. This accounts for possible reduced hepatic or renal function in this population.


Q: Do you need a prescription to get T98?

According to regulatory classification, T98 (which is the active ingredient Acetaminophen/Paracetamol) is widely available as an Over-the-Counter (OTC) medication.

This means it can generally be purchased without a prescription.


Q: How quickly does T98 start to have an effect?

Studies examining the medicine's absorption indicate that following oral administration, T98's concentration in the blood typically reaches its peak within 30 to 60 minutes.

This time to peak concentration suggests when the maximum symptomatic relief is generally achieved.


Q: Can T98 be crushed or opened if a person has trouble swallowing?

Official labeling specifies that certain dosage forms, such as modified-release or extended-release tablets, are intended to be swallowed whole.

Manipulating these particular forms by cutting, crushing, chewing, or dissolving them can disrupt the medicine’s intended timed release and should be avoided.


Q: Can T98 cause sleep problems like insomnia or excessive tiredness?

Official product labeling for single-agent T98 does not commonly include insomnia as a frequent adverse effect.

However, studies and official information indicate that long-term use of the medicine has been associated with general tiredness or fatigue.


Q: Are there any known food interactions with T98?

Regulatory documents warn about a specific interaction relevant to certain T98 formulations.

Chewable tablets or liquid forms may contain aspartame, which the body converts into phenylalanine, a substance that requires caution for individuals diagnosed with Phenylketonuria (PKU).


Q: Are there special considerations for people with diabetes or high blood pressure when taking T98?

T98 is generally considered suitable for individuals with high blood pressure, as it is not classified as a nonsteroidal anti-inflammatory drug (NSAID).

For individuals with diabetes, certain liquid or chewable formulations may contain sugar or artificial sweeteners like aspartame, which may be a relevant factor.


Q: Are there any official reports of T98 causing dependence or withdrawal symptoms?

Official product labeling for single-agent T98 (Acetaminophen/Paracetamol) does not contain warnings regarding physical dependence or withdrawal symptoms.

Regulatory agencies mandate these specific warnings primarily for medicines combined with substances like opioids.


Q: Is it necessary to avoid driving or operating heavy machinery when starting T98?

Official product labels for single-agent T98 typically do not contain general warnings to restrict driving or operating heavy machinery.

Restrictions are usually advised only if the user experiences individual adverse effects, such as drowsiness or dizziness.


Q: Are there any tests required before or during treatment with T98?

Routine monitoring tests are not generally required for all users.

However, regulatory documents state that monitoring of hepatic function (liver function) may be recommended for patients with existing liver impairment, due to the drug’s potential risk of liver damage.


Q: How long after stopping T98 does it take for the drug to be fully out of the system?

Pharmacokinetic studies indicate that T98 has an elimination half-life of approximately one to three hours.

This means that, based on this measurement, the medicine is typically considered to be fully cleared from the body within 5 to 15 hours after the final dose.

Advertisements

How should T98 be stored and disposed of?

How to Store and Dispose of T98

The storage and disposal of T98 (Paracetamol/Acetaminophen) must comply strictly with official labeling to ensure product stability and safety.

Official Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at a controlled room temperature, typically between 20 C and 25 C (or below 30 C).
Protection Keep the medicine in its original, tightly closed container; protect from light and moisture.
Prohibition The product must not be frozen and should be kept out of excessive heat.
Safety It is mandatory to keep T98 out of the sight and reach of children.

Official Disposal Rules

Unused or expired T98 should be discarded via an official medicine take-back program if available. If no program exists, the medicine may be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a plastic bag, and placed in the household trash. The product should generally not be disposed of by flushing down a toilet or pouring down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of T98 found in:

A-Z Index: